Johnson & Johnson Shares Sink as Profit Miss, MedTech Weakness and Litigation Costs Shake Investors
Johnson & Johnson shares fell as much as 6.8% after the healthcare giant reported a sharp drop in quarterly profit, even as it lifted its full-year earnings outlook. Investors focused on weaker-than-expected MedTech performance and litigation-related charges, which overshadowed revenue growth and an adjusted earnings beat. The reaction underscores how sensitive the stock remains to margin pressure and legal overhangs despite the company’s defensive profile.
